Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen S.A. (OP: IPSEF ) 117.61 UNCHANGED Last Price Updated: 9:48 AM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 117.61 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 117.61 Today's Range 117.61 - 117.61 52wk Range 108.75 - 117.61 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur May 22, 2023 On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... Via Benzinga Performance YTD +0.31% +0.31% 1 Month N/A N/A 3 Month N/A N/A 6 Month N/A N/A 1 Year +8.15% +8.15% More News Read More France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline January 09, 2023 Via Benzinga Why Merrimack Shares Are Surging Over 200% Today? November 09, 2022 Via Benzinga Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure August 03, 2022 Via Benzinga Why Is Epizyme (EPZM) Stock Up 75% Today? June 27, 2022 Via InvestorPlace Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why June 27, 2022 Via Benzinga Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer May 03, 2022 Via Benzinga EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer March 25, 2022 Via Benzinga Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease January 24, 2022 Via Benzinga Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful December 17, 2021 Via Benzinga Ipsen Stock Declines After Pulling Rare Disease Application August 13, 2021 Via Benzinga Exposures Product Safety Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders August 02, 2021 Via Benzinga Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics July 27, 2021 Via Benzinga Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer June 28, 2021 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.